Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
Ryan Allway January 19th, 2022 Psychedelics VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials of Investigational Medicinal... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )